IRF4 and diffuse large B-cell lymphoma: The JAK/STAT inhibitor + BTK inhibitor Ibrutinib in combination bypassed survival stimuli from bone marrow mesenchymal stromal cells to induce cell death in CLL [155] and induced IRF4 levels to synergistically kill ABC-DLBCL cells [93].